Soleno Therapeutics Inc (NASDAQ: SLNO)

Soleno Therapeutics Inc is a biopharmaceutical company focused on developing novel therapeutics for rare diseases. Its lead product candidate, VYKAT XR (diazoxide choline) extended release tablets, received approval from the U. S. Food and Drug Administration on March 26, 2025 for the treatment of hyperphagia in adults and pediatric patients aged 4 years and older with Prader Will syndrome. VYKAT XR contains diazoxide choline, a potent ATP sensitive potassium channel activator that modulates neuronal and metabolic pathways implicated in appetite regulation. The company is headquartered in Redwood City, California and operates in the biopharmaceutical industry. Soleno Therapeutics aims to address the significant unmet medical need for effective therapies that reduce excessive food intake and improve behavioral outcomes in Prader Will syndrome patients. Beyond PWS, the company’s patent portfolio includes compositions and methods relevant to Smith-Magenis syndrome, suggesting potential future expansion of its therapeutic pipeline. Soleno Therapeutics continues to invest in research and development to identify additional rare disease indications where its K ATP modulator platform may provide clinical benefit.

We generate revenue primarily from the sale of VYKAT XR, which is priced on a weight based basis at $6.0976 per milligram. The product is distributed through a specialty pharmacy network that dispenses the medication upon receipt of a prescription from a qualified healthcare provider. Initial shipments to patients began in April 2025 and the company started recognizing revenue from VYKAT XR sales during the quarter ended June 30, 2025. In addition to direct product sales, Soleno Therapeutics offers patient support programs through its SOLENO ONE platform that provide education, counseling and financial assistance where applicable. These support initiatives do not constitute a separate revenue stream but are designed to improve access and adherence to the prescribed therapy. Manufacturing of VYKAT XR is outsourced to third party contract manufacturing organizations that handle active pharmaceutical ingredient production, drug product formulation, packaging and distribution under strict quality and regulatory oversight.

Soleno Therapeutics occupies a pioneering position as the first company to secure FDA approval for a treatment targeting hyperphagia in Prader Will syndrome patients. While growth hormone products are approved for growth failure in PWS, they do not affect appetite control, leaving a clear unmet need that VYKAT XR fulfills. The orphan drug designation granted to VYKAT XR provides up to 7 years of market exclusivity in the United States for the approved indication. Market research estimates that approximately 300,000 to 400,000 individuals worldwide live with Prader Will syndrome. Based on analyses of claims data, Soleno Therapeutics has identified roughly 10,000 individuals who have received a PWS specific treatment or carried a PWS related ICD10 code in 2022 or 2023. Several biotechnology firms, including Aardvark Therapeutics, Bright Minds Biosciences, Consynance, Harmony Biosciences, Neuren Pharmaceuticals, OT4B, Palobiofarma and Rhythm Pharmaceuticals, have drug candidates in various stages of development for PWS related hyperphagia and behavioral symptoms. The company’s competitive advantages stem from the novel mechanism of diazoxide choline as a K ATP channel activator, its extended release formulation enabling once daily dosing, and the potential to improve multiple disease manifestations such as insulin resistance and body composition. Soleno Therapeutics also benefits from a focused commercial organization of approximately 65 field personnel, including rare disease specialists and clinical nurse educators, which supports targeted outreach to prescribing physicians and treatment centers. The combination of regulatory exclusivity, differentiated pharmacology and a dedicated sales force positions the company to capture a meaningful share of the diagnosed PWS population in the United States.

The company serves patients diagnosed with Prader Will syndrome, a rare genetic disorder affecting both genders and occurring in approximately 1 in every 15,000 live births. These patients are typically managed by multidisciplinary care teams led by pediatric or adult endocrinologists and often receive care at specialized clinics, university affiliated hospitals or residential group home settings. Treatment is initiated following a prescription from a qualified healthcare provider and the medication is dispensed through specialty pharmacy channels that handle prior authorization and delivery to the patient’s home or care facility. Caregivers and family members play an important role in monitoring adherence and supporting lifestyle adjustments that complement the pharmacological intervention. No specific customer names are disclosed in the filing, but the target population includes both pediatric and adult individuals living with Prader Will syndrome. The company’s commercial organization engages with prescribing physicians, pharmacists and care coordinators to ensure appropriate use of VYKAT XR within the prescribed treatment paradigm.